QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Phase Ib/II Study of ALT-803 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Pancreatic Cancer
Sponsor: Altor BioScience
Listed as NCT02559674, this PHASE1 trial focuses on Advanced Pancreatic Cancer and remains completed. Sponsored by Altor BioScience, it has been updated 10 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Sep 2019 — Feb 2020 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting · Phase: PHASE1_PHASE2 → PHASE1
-
Sep 2017 — Feb 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Altor BioScience
For direct contact, visit the study record on ClinicalTrials.gov .